Figure S4 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

Key Points

• B7-H3 CAR T cells are effective against ependymomas, yet their efficacy diminishes with larger tumors.
• Antigen profiling of HER2 reveals its status in ZFTA-fusion driven EPN cell lines, emphasizing a potential therapeutic target.
• The immune response presents a challenge for B7-H3 CAR T cell therapy, as heightened resistance may limit effectiveness.
• Findings indicate a need for strategies to enhance B7-H3 CAR T cell functionality in the face of tumor size variations.